Vancomycin-Resistant Enterococcus Faecium Infections - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: V71A78D3713EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Vancomycin-Resistant Enterococcus Faecium Infections - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Vancomycin-Resistant Enterococcus Faecium Infections epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Vancomycin-Resistant Enterococcus Faecium Infections Understanding

The DelveInsight Vancomycin-Resistant Enterococcus Faecium Infections epidemiology report gives a thorough understanding of the Vancomycin-Resistant Enterococcus Faecium Infections by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Vancomycin-Resistant Enterococcus Faecium Infections in the US, Europe, and Japan. The report covers the detailed information of the Vancomycin-Resistant Enterococcus Faecium Infections epidemiology scenario in seven major countries (US, EU5, and Japan).

Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Perspective by DelveInsight

The Vancomycin-Resistant Enterococcus Faecium Infections epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Vancomycin-Resistant Enterococcus Faecium Infections epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Vancomycin-Resistant Enterococcus Faecium Infections epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Vancomycin-Resistant Enterococcus Faecium Infections Detailed Epidemiology Segmentation

The Vancomycin-Resistant Enterococcus Faecium Infections epidemiology covered in the report provides historical as well as forecasted Vancomycin-Resistant Enterococcus Faecium Infections epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Vancomycin-Resistant Enterococcus Faecium Infections report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Vancomycin-Resistant Enterococcus Faecium Infections report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Report and Model provide an overview of the global trends of Vancomycin-Resistant Enterococcus Faecium Infections in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Vancomycin-Resistant Enterococcus Faecium Infections in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Vancomycin-Resistant Enterococcus Faecium Infections
• The report provides the segmentation of the Vancomycin-Resistant Enterococcus Faecium Infections epidemiology

Report Highlights

• 11-year Forecast of Vancomycin-Resistant Enterococcus Faecium Infections epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Vancomycin-Resistant Enterococcus Faecium Infections
• Cases of Vancomycin-Resistant Enterococcus Faecium Infections by Mutation Types
• Vancomycin-Resistant Enterococcus Faecium Infections Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Vancomycin-Resistant Enterococcus Faecium Infections?
• What are the key findings pertaining to the Vancomycin-Resistant Enterococcus Faecium Infections epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Vancomycin-Resistant Enterococcus Faecium Infections across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Vancomycin-Resistant Enterococcus Faecium Infections?
• What are the currently available treatments of Vancomycin-Resistant Enterococcus Faecium Infections?

Reasons to buy

The Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Vancomycin-Resistant Enterococcus Faecium Infections market
• Quantify patient populations in the global Vancomycin-Resistant Enterococcus Faecium Infections market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Vancomycin-Resistant Enterococcus Faecium Infections therapeutics in each of the markets covered
• Understand the magnitude of Vancomycin-Resistant Enterococcus Faecium Infections population by its epidemiology
• The Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS

3. VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM INFECTIONS: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Vancomycin-Resistant Enterococcus Faecium Infections Treatment and Management
6.2. Vancomycin-Resistant Enterococcus Faecium Infections Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in 7MM (2019-2032)
Table 2: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in the United States (2019-2032)
Table 4: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Germany (2019-2032)
Table 6: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in France (2019-2032)
Table 8: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Italy (2019-2032)
Table 10: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Spain (2019-2032)
Table 12: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in the United Kingdom (2019-2032)
Table 14: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Japan (2019-2032)
Table 16: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in 7MM (2019-2032)
Figure 2 Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in the United States (2019-2032)
Figure 4 Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Germany (2019-2032)
Figure 6 Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in France (2019-2032)
Figure 8 Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Italy (2019-2032)
Figure 10 Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Spain (2019-2032)
Figure 12 Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in the United Kingdom (2019-2032)
Figure 14 Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Japan (2019-2032)
Figure 16 Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report